Sarepta’s stock price plummets after an ‘erroneous’ report
KRISTOFFER TRIPPLAAR/SIPA USA)(SIPA VIA AP
Shares plummeted after an analyst discovered that a patient in one of the company’s trials for Duchenne muscular dystrophy reported a serious side effect.
No hay comentarios:
Publicar un comentario